KRAS and breast carcinoma: Ribociclib exhibited higher IC50 values in DLD-1 (PIK3CA/KRAS-mutated) and Caco-2 (PIK3CA/KRAS wild-type) lines (IC50 >15 μM) compared to breast cancer models, though values for the SNUC4 (PIK3CA-mutated) and LS1034 (KRAS-mutated) lines were comparable [25].